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Cytoplasmic dynein is the most important molecular motor driving the movement of a wide range of cargoes towards the mi-
nus ends of microtubules. As a molecular motor protein, dynein performs a variety of basic cellular functions including orga-
nelle transport and centrosome assembly. In the nervous system, dynein has been demonstrated to be responsible for axonal 
retrograde transport. Many studies have revealed direct or indirect evidence of dynein in neurodegenerative diseases such as 
amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, Alzheimer’s disease, Parkinson’s disease and Huntington’s dis-
ease. Among them, a number of mutant proteins involved in various neurodegenerative diseases interact with dynein. Axonal 
transport disruption is presented as a common feature occurring in neurodegenerative diseases. Dynein heavy chain mutant 
mice also show features of neurodegenerative diseases. Moreover, defects of dynein-dependent processes such as autophagy or 
clearance of aggregation-prone proteins are found in most of these diseases. Lines of evidence have also shown that dynein is 
associated with neurodevelopmental diseases. In this review, we focus on dynein involvement in different neurological diseas-
es and discuss potential underlying mechanisms. 
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Mammalian cytoplasmic dynein was first identified and 
characterized as a high molecular weight microtubule-  
activated ATPase and the major microtubule minus 
end-directed motor protein of the cell in 1987 [1]. It has also 
recently emerged as an important player in various neuro-
logical diseases. 
Cytoplasmic dynein is a large complex, consisting     
of heavy chains (HCs, 530 kD), intermediate chains (ICs,  
74 kD), light intermediate chains (LICs, 5359 kD), and 
light chains (LCs, 1014 kD). The HCs are encoded by only 
one gene, ICs, LICs and LCs are each encoded by two 
genes in vertebrates [2]. 
The precise structure of the intact complex is still un-
known, but at its core lies a homodimer of heavy chains. 
The C-terminal region of this homodimer of the heavy chain 
is conserved and is the motor domain of the dynein complex 
involved in binding and hydrolysis of ATP for energy [3]. 
The N-terminal region of the dynein heavy chain is known 
as the stem domain and contains binding positions for LICs 
and ICs. LCs bind to the IC at separate sites. The ICs, LICs 
and LCs together, form the cargo binding domain of cyto-
plasmic dynein [4] (Figure 1). 
Dynactin is a key subunit of the dynein complex. It is an 
important cofactor of the microtubule (MT) motor, with the 
dynactin p150Glued subunit interacting directly with the ICs.  
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Figure 1  Structure of dynein-dynactin complex. Cartoon view of 
dynein-dynactin complex. The carboxy-terminal half of heavy chain subu-
nits (DYNC1H1) are comprised by seven AAA-ATPase domains (labeled 
16 and C). In amino terminal, the dynein intermediate chains (DYNC1I), 
light chains (DYNLT, DYNLL and DYNLRB), light-intermediate chains 
(DYNC1LI) and DYNC1H1 together form the cargo binding domain of 
dynein. Dynactin, which is a cofactor for the dynein, is itself a large protein 
complex with various subunits including p150Glued, Arp1, p62 and p50. 
Cargo binding of dynein-dynactin complex requires the interactions of 
Arp1 and other proteins like β3-Spectrin. 
Dynactin also indirectly binds to the minus-end directed 
MTs as well as MT plus-end binding proteins [5,6]. It has 
been reported that the dynactin complex can enhance 
dynein’s processivity without changing its rate of move-
ment or ability to undergo retrograde transport [7,8]. 
Cytoplasmic dynein plays crucial roles in cell survival, 
by mediating retrograde transport of various proteins/  
protein complexes and membranous organelles. It is also 
important for cell division and cell differentiation [2,3,8]. 
The importance of dynein and its regulators is highlighted 
by their roles in the translocation of centrosomes along mi-
crotubules during mitosis, cell and nuclear migration and 
organelle transport [911]. The molecular interactions reg-
ulating dynein activity have recently been elucidated. It has 
been shown that lissencephaly 1 (LIS1), nuclear distribution 
protein E (NudE; also known as NdE), NudE-like (NudEL; 
also known as NdEL), Bicaudal D, ROD-ZW10-Zwilch 
(RZZ) and spindly are required for dynein function [12]. 
For example, these interactions play a crucial part in mitosis, 
including mitotic spindle orientation, nuclear and centro-
somal transport in neuronal migration, centrosome posi-
tioning in non-neuronal cell migrating and growth cone ex-
tension [13]. 
Considerable evidence has shown that dysfunction of the 
dynein-dependent signaling pathway, and in particular, ret-
rograde transport in neurons, results in various neurological 
diseases, exemplifying the clinical significance of dynein. 
This review will focus mainly on dynein-related neural dis-
eases and present some possible mechanisms underlying the 
pathogenesis of these diseases. 
1  Dynein in neurodegenerative diseases 
Amyotrophic lateral sclerosis (ALS) is a fatal and progres-
sive neurodegenerative disorder affecting motor neurons in 
the motor cortex, brainstem and spinal cord and typically 
leads to muscle weakness, muscle atrophy and death within 
about 5 years of onset. Sporadic ALS and autosomal domi-
nant familial ALS (FALS) present with similar symptoms 
[1416]. About 10% of ALS cases are inherited as an auto-
somal dominant trait, among which 15%20% are found 
related to Cu/Zn superoxide dismutase (SOD1) gene muta-
tions [17]. To date, more than 100 different mutations have 
been found in the SOD1 gene, and over 10 different genetic 
mouse models mimicking human MND pathology have 
been established [18] (http://ghr.nlm.nih.gov/gene/SOD1). 
Swl, Cra1 and Loa are three different mutations in the 
dynein heavy chain. Loa and Cra1 are two different point 
mutations in Dync1h1. Swl is 9-bp deletion in Dync1h1 that 
changes the four residues from position 10401043 into a 
single alanine, and it lies close to the Cra1 mutation. Lines 
of evidence have indicated that an involvement of dynein in 
SOD1 axonal transport deficit may be crucial in selective 
motor neuron degeneration in ALS. It was found that during 
embryonic development retrograde axonal transport defects 
were present in motor neurons of SOD1G93A mice which has 
a significantly reduced life span. However, after crossing 
SOD1G93A mice with Loa/+, double mutants Loa/SOD1G93A 
showed delayed disease progression and a significantly in-
creased life span, with complete recovery in axonal 
transport deficits in motor neurons [19]. Cra1/+ showed 
similar results when crossed with SOD1G93A mice [20]. 
Studies have shown that SOD1 carrying ALS-linked muta-
tions interacted and colocalized with the DYNC1H1 in vitro 
and in vivo [21]. It was proposed that the misfolded SOD1 
mutants acquired an aberrant “gain-of-interaction” with 
dynein, thus overloading dynein-mediated retrograde tran- 
sport and impairing axonal transport in motor neurons 
which ultimately led to motor neuron death [21]. However, 
mutant DYNC1H1 weakens this “gain-of-interaction”, thus 
life span improvement in Loa/SOD1G93A mice may occur by 
rescuing the balance between anterograde and retrograde 
transport. Thus DYNC1H1 may ultimately ameliorate the 
loss of axonal homeostasis or rescue the imbalance of retro-
grade and anterograde axonal input [19,22]. 
Interestingly, our previous study has indicated that Swl/+ 
mice harboring a nine-base pair deletion within exon 12 of 
Dync1h1, whose mutation located in dynein cargo binding 
domain, exhibit sensory neuropathy. More specifically, the 
Swl mice only exhibited sensory neuropathy without motor 
neuronal deficits, while Loa/+ and Cra1/+ mice mainly 
displayed motor neuropathy [23]. In contrast to Loa/+ mice, 
the Swl/+ mutation did not attenuate disease progression in 
SOD1G93A mice in an intercross study [24]. This finding 
seems to contradict the study of Loa/SOD1G93A mice or 
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Cra1/SOD1G93A mice, but can be explained in two ways: 
firstly, different Dync1h1 mutations could affect the affinity 
between dynein cargo binding domains and cargos. This 
would result in changes in the ability to transport cargos and 
cause different pathological severity. In Swl/+ mice, the 
nine-base pair deletion of Dync1h1 may result in a small 
change in affinity of the dynein-dynactin complex for some 
cargos. This lower affinity may not be enough to induce 
observable changes in motor neurons but may do so in sen-
sitive proprioceptive sensory neurons. Secondly, it is possi-
ble that different Dync1h1 mutations may lead to selective 
cargo transport impairment thus induce selective neuronal 
degeneration [24]. 
Additional evidence has shown that mutant SOD1 can 
localize in mitochondria and disrupt mitochondria function 
[25]. As mitochondria and mutant SOD1 can both interact 
with dynein, it is possible that dynein-related accumulation 
of mutant SOD1 in mitochondria may lead to the direct im-
pairment of mitochondrial function and the induction of 
neural degeneration. Dynein may also be important in 
SOD1 degradation as cells may utilize dynein-mediated 
transport to collect mutant SOD1 and form aggresomes for 
autophagic degradation [26]. Nevertheless, these findings 
still do not fully account for the pathogenesis of the selec-
tive neural degeneration seen in ALS, because the SOD1 
mutation itself can only be found in some cases of FALS. 
Other hypothesized mechanisms of dynein involvement 
in MND/ALS focus on the disturbance of retrograde trans-
portation of some important cargos. Neurotrophic factors 
such as nerve growth factor (NGF), brain-derived neu-
rotrophic factor (BDNF), and neurotrophin 3 (NT-3) are 
secreted by target tissues in early embryonic stages and 
subsequently bind to tyrosine kinase (Trk) receptors on the 
surface of neurons. Aberrant dynein complexes may under-
mine the retrograde transport of these endocytosed Trk re-
ceptors and downstream components to the soma, resulting 
in neural degeneration. However, some key questions re-
main, including which phase of disease progression is af-
fected and which neurotrophins are required by individual 
neuron subtypes? This information is necessary to under-
stand the role of Trk retrograde transport in selective neuron 
degeneration. Therefore, the pathological relationship be-
tween dynein and ALS still warrants further exploration.  
2  Charcot-Marie-Tooth (CMT) disease  
CMT is the most prevalent hereditary peripheral neuropathy 
affecting both motor and sensory nerves and has an esti-
mated incidence of one in 2500 [27]. Clinically, it is char-
acterized by distal limb muscle wasting and weakness, usu-
ally with skeletal deformities, distal sensory loss, and loss 
of deep tendon reflexes [28]. There are two main forms of 
CMT: demyelinating type 1 (CMT1) and axonal type 2 
(CMT2) [29]. More than 40 loci and 30 genes have been 
identified in CMT (http://www.molgen.ua.ac.be/CMT-Mu- 
tations/ Mutations/MutByGene.cfm). 
In a study of a CMT2 family with 23 members, three af-
fected individuals were found to share a novel heterozygous 
variant DYNC1H1c.917A>G using exome sequencing 
method [30]. This mutation resulted in a missense substitu-
tion, p.His306Arg, at a highly conserved residue within the 
homodimerization domain. Affected patients typically have 
early-onset slowly progressive distal lower limb weakness 
and wasting with pes cavus deformity [30]. These patients 
shared some typical features with animal models of Swl/+, 
Loa/+ and Cra1/+ that exhibit age-related progressive loss 
of muscle bulk and locomotor ability without a major re-
duction in life span.  
The mechanisms underlying the CMT2 phenotype are 
still unknown, but increasing evidence has suggested that 
dynein is associated with this type of hereditary neuropa-
thies. CMT2B is caused by the G-protein Rab7 mutation [31] 
and Rab7 controls dynein/dynactin recruitment to lyso-
somes and late endosomes through its effector protein RILP 
[32]. In CMT2E, mutant NF-L (neurofilament light) aggre-
gates disturb microtubules and disrupt the normal localiza-
tion of mitochondria [33]. Additionally, in the CMT2A 
mouse model, axonal transport of mitochondria is compro-
mised [34]. Furthermore, the overexpression of CMT2E- 
linked NF-L leads to impaired axonal transport [35].  
  However, there is much debate about the exact roles of 
dynein in CMT disease. In 2003, Loa/+ was reported to 
affect motor neurons in the spinal anterior horn [36]. While 
our study suggested that Loa/+ mice also suffered from 
early-onset proprioceptive sensory neuropathy or possibly 
primary effects on the sensory neurons. A recent study by 
Wiggins [37], found that Loa/+ mice displayed deficits in 
both the motor and sensory nervous system. This argues 
against a model primarily involving sensory loss. This study 
found abnormal dendrites in large trigeminal motor neurons 
which is consistent with the findings in Cra1/+ mice [38]. 
The phenotype of the Loa/+ mouse differs considerably 
between the cranial and the spinal levels of the neuraxis. 
-motoneuron loss in the trigeminal motor nucleus was 
already apparent at an early postnatal age and progressed 
only minimally with age [37]. These findings give rise to 
questions of how dynein dysfunction results in selective 
neural degeneration, especially selective motor neuron de-
generation. Which type of neuron is affected in CMT dis-
ease? What is the ‘trigger’ substance initiating CMT disease 
onset and progression?  
Some clues suggest neurotrophic factors are involved in 
the pathogenesis of the disease. In fact, each factor func-
tions during discrete developmental periods and target se-
lection occurs at different time-points. For example, NT-3 
signaling significantly affects neurons in the lumbar spinal 
cord, in contrast to those innervating the mastication mus-
cles of the jaw [37,39]. Aberrant neurofilament accumula-
tion in Loa/+ and Cra1/+ mice may explain the motor neu-
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ron degeneration as being the result of dynein-mediated 
dysfunction of transport [40]. To date, many studies show a 
close relationship between dynein and CMT2 disease. 
However, the mechanisms of dynein-dependent pathology 
underlying CMT2 pathology in patients and related mouse 
models need further exploration.  
3  Alzheimer’s disease (AD) 
Alzheimer’s disease is the most common form of dementia 
and most often diagnosed in the elderly over 65 years of age. 
Alzheimer’s disease has some general symptoms including 
progressive and irreversible cognitive deterioration with 
memory loss, impaired judgment and language, and other 
cognitive deficits and behavioral symptoms. Loss of body 
function can lead ultimately to death [41]. The typical 
pathological features are neurofibrillary tangles (NFTs) 
caused by tau protein deposits inside the neurons [42] and 
senile plaques (SPs). SPs are dense, mostly insoluble depos-
its of beta-amyloid peptide and cellular material outside and 
around the neuron [42]. The cause and progression of Alz-
heimer’s disease are not well understood. APP is the pre-
cursor of Aβ peptide and is transported by fast axonal ante-
rograde transport [43]. Aβ peptide has been shown to dis-
rupt axonal transport in vitro [44]. Axonal transport is also 
compromised in aged brains [44]. Several lines of evidence 
investigating the link between axonal transport machinery 
and amyloid plaques suggested an involvement of antero-
grade transport rather than retrograde transport [45]. Studies 
of axonal transport revealed interactions between AD-  
associated proteins and dynein. In an AD animal model, 
aged cynomolgus monkeys, researchers found that 
AD-associated proteins accumulated in the axon terminals 
and that DIC-DYN (dynactin) significantly increased along 
with axonal transport motor protein accumulation [46]. 
Rab5, which has been reported to depend on dynein in en-
docytosis, stimulated up-regulation of the endocytic path-
way and increased intracellular Aβ production [47]. Fur-
thermore, tau hyperphosphorylation has been observed in 
AD [48,49]. Somatic localization of phospho-tau, a cyto-
skeletal protein, is indicative of cytoskeletal breakdown [50]. 
A recent study indicates that altered cellular distribution of 
phospho-tau protein coincided with impaired retrograde 
axonal transport in neurons of aged rats, suggesting that 
failure of axonal trafficking may be responsible for the lack 
of neurotrophic support in aged cholinergic neurons of the 
basal forebrain [50]. It is also possible that tau hyperphos-
phorylation contributes to cytoskeletal instability, thereby 
impairing dynein’s normal function. Perhaps dynein acts in 
association with tau and APP to promote AD progression. 
To date, most studies have shown an indirect relationship 
between dynein and AD. However direct evidence linking 
AD-related proteins and dynein is anticipated. 
4  Parkinson’s disease (PD) and Huntington 
disease (HD) 
PD is one of the most common degenerative disorder of the 
central nervous system. Its typical symptoms are resting 
tremor, rigidity, slowness of movement, and postural insta-
bility. PD results from the loss of dopamine-generating cells 
in the substantia nigra. Mutations in Parkin, α-synuclein, 
PINK1, and DJ1 are associated with PD. HD, another basal 
ganglia degenerative disease, has typical features including 
loss of muscle coordination, cognitive decline and psychiat-
ric symptoms. These symptoms appear in mid-adult life. 
HD is caused by an expanded CAG repeat in exon 1 of the 
gene coding for the huntingtin protein [51]. Perry syndrome 
is an atypical PD syndrome resistant to L-DOPA, charac-
terized by early-onset parkinsonism, depression, severe 
weight loss and hypoventilation, with brain pathology char-
acterized by TDP-43 immunostaining [52]. There is some 
evidence that dynein plays an important part in PD/HD pro-
gression. Lewy bodies are abnormal protein aggregates that 
develop inside nerve cells in PD. In animal models, 
Lewy-like intracellular inclusion bodies in surviving neu-
rons were observed in heterozygous Cra1/+ mice [36]. Ad-
ditionally, Cra1/+ mice display motor and behavioral ab-
normalities resembling HD and Perry syndrome [36]. These 
mice also display striatal atrophy and ventricle enlargement 
without striatal or substantia nigra dopaminergic neuronal 
loss. Dynein mutant striatal neurons also exhibit strongly 
disrupted neurite morphology in vitro. Additionally, ge-
nome-wide linkage analysis has identified disease-    
segregating dynactin CAP-Gly domain substitutions that 
diminish microtubule binding and lead to intracytoplasmic 
inclusions [52]. Since dynactin is an important regulator of 
dynein, Perry syndrome may be closely related to the dis-
ruption of dynein function. However, we are a long way 
from fully understanding the mechanism by which dynein 
contributes to PD and HD. 
5  Dynein in neurodevelopmental diseases 
As a house keeping protein, dynein is not only important in 
neural degeneration, but is also crucial in neural develop-
ment, including neurogenesis and neuronal migration.  
LIS1 was reported to facilitate the activity of cytoplasmic 
dynein, interacting directly with the cytoplasmic dynein 
heavy chain (CDHC) and NudEL and its ortholog NudE. 
LIS1 and NudEL/NudE are important dynein interactors in 
the cytoplasmic dynein pathway [13]. Studies have shown 
that both LIS1 and NudEL are required for cell migration, 
nuclear, centrosomal, microtubule transport, mitosis, and 
growth cone motility [5356]. It has been reported that the 
LIS1/ NudEL /dynein pathway is involved in neuronal mi-
gration and positioning during cortical development and is 
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therefore essential for proper brain function [57]. The LIS1 
gene is responsible for human lissencephaly (smooth brain), 
which is a neuronal migration disorder resulting from a 
failure or delay in neuronal migration and severe abnormal-
ities in cortical layering [58]. LIS1 and NudEL are colocal-
ized predominantly at the centrosome in early neuroblasts 
but are redistributed to axons via dynein. NudEL and LIS1 
regulate the distribution of CDHC along microtubules and 
consequently affect CDHC activity during neuronal migra-
tion and axonal retrograde transport in a Cdk5/p35 (NudEL 
phosphorylator)-dependent manner [55]. As LIS1 and 
NudEL are regulators of dynein function, they may provide 
insights into important cell functions underlying neurode-
velopmental diseases.  
6  Conclusion 
In summary, as a key retrograde transport protein, cyto-
plasmic dynein has increasingly attracted attention from 
researchers because of its important roles in retrograde ax-
onal transport and its association with various neurological 
disorders. To date, studies have largely focused on 
dynein-cytoskeletal motor interactions and the link between 
disrupted dynein function and disease morphology. There-
fore, further research is required to reveal the molecular 
mechanisms through which dynein subunits or dynein regu-
lators trigger neurodegenerative disease and potentiate its 
progression. In conclusion, the mechanisms underlying mo-
lecular cross-talk between cytoplasmic dynein and dynein- 
interacting proteins warrant further study. 
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